➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Harvard Business School
Johnson and Johnson
McKesson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,427,578


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,427,578
Title:Pharmacokinetics of iontophoretic sumatriptan administration
Abstract: Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Inventor(s): Sebree; Terri B. (Gladwyne, PA), Pierce; Mark (Essex, CT), O'neill; Carol (Phoenixville, PA)
Assignee: Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Application Number:14/185,485
Patent Claims: 1. A method for treating a sumatriptan responsive state in a human in need thereof, comprising iontophoretically delivering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first portion of a treatment period for about one hour without substantially irritating said human's skin, such that said sumatriptan responsive state in said human is treated.

2. The method of claim 1, wherein an effective amount of the sumatriptan, or the salt thereof, delivered systemically is greater than 5 mg.

3. The method of claim 1, wherein the sumatriptan, or salt thereof, is sumatriptan succinate.

4. The method of claim 1, wherein the method further comprises iontophoretically administering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 2 mA during a second portion of the treatment period.

5. The method of claim 4, wherein the effective amount of sumatriptan, or salt thereof, delivered systemically to said human is greater than 5 mg.

6. The method of claim 5, wherein the sumatriptan, or salt thereof, is sumatriptan succinate.

7. The method of claim 6, wherein the sumatriptan responsive state is migraine.

8. An iontophoretic patch designed to iontophoretically deliver to a human sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first treatment period for about one hour, without substantially irritating said human's skin.

9. The patch of claim 8, wherein the patch systemically delivers greater than 5 mg of sumatriptan or salt thereof.

10. The patch of claim 8, wherein the sumatriptan, or salt thereof, is sumatriptan succinate.

11. The patch of claim 8, wherein the patch is further designed to iontophoretically deliver sumatriptan, or a salt thereof, using a current of 2 mA during a second treatment period.

12. The patch of claim 11, wherein an amount of sumatriptan, or the salt thereof, delivered systemically to said human is greater than 5 mg.

13. The patch of claim 12, wherein the sumatriptan, or salt thereof, is sumatriptan succinate.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
McKinsey
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.